EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety of Intravenous Edaravone in Clinical Practice

Angela Genge, Stephen Apple iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Angela Genge und 1 weiteren Autor:innen. Beteiligte Einrichtung: Montreal Neurological Institute and Hospital, Montreal, Canada. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Antipyrine, Free Radical Scavengers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mitsubishi Tanabe Pharma America, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article summarizes the post‐marketing pharmacovigilance safety data of intravenous (IV) edaravone during the 1‐ and 3‐year periods following its launch for amyotrophic lateral sclerosis (ALS) in the United States. The most frequently reported adverse events (AEs) and serious AEs (SAEs) included those consistent with ALS disease progression, such as fatigue and muscular weakness, and were not qualitatively different from those reported in previous ALS trials. There were AEs and SAEs associated with IV administration, such as administration site reactions, and five non‐fatal anaphylaxis SAEs were reported. No new safety signals were identified, and IV edaravone continues to demonstrate a favorable safety profile. These insights are especially useful as treatment transitions to edaravone oral suspension, which avoids IV‐related complications. These findings underscore the importance of ongoing clinical safety assessments in informing ALS treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisAntipyrineFree Radical ScavengersHumansEdaravoneAdministration, IntravenousFemalePharmacovigilanceMaleMiddle AgedAged

Stichwörter der Autor:innen

amyotrophic lateral sclerosisclinicaledaravonepharmacovigilancesafety

Substanzen

EdaravoneAntipyrineFree Radical Scavengers

Autor:innen und Institutionen

  • Montreal Neurological Institute and Hospital, Montreal, Canada.
  • Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.

ORCID-Profile: Stephen Apple

Förderung

  • Mitsubishi Tanabe Pharma America, Inc.

Zitieren

APA

Genge, A., & Apple, S. (2026). Safety of Intravenous Edaravone in Clinical Practice. Muscle & Nerve. https://doi.org/10.1002/mus.70038

Vancouver

Genge A, Apple S. Safety of Intravenous Edaravone in Clinical Practice. Muscle & Nerve. 2026. doi:10.1002/mus.70038

BibTeX
@article{Genge2026,
  author = {Genge, Angela and Apple, Stephen},
  title = {Safety of Intravenous Edaravone in Clinical Practice},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70038}
}
Kostenlos starten →